trial

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia

NCTId NCT04109950
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment 463 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2023-11-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
463 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-11-20
Primary completion
2023-11-09
Eligibility
ALL · 13 Years · 65 Years

Interventions & indications

Drugs
Ulotaront

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

78 total
Little Rock, United StatesRogers, United StatesAnaheim, United StatesCulver City, United StatesLemon Grove, United StatesLong Beach, United StatesLong Beach, United StatesMontclair, United StatesSan Diego, United StatesSherman Oaks, United StatesMiami Springs, United StatesOakland Park, United States

Linked catalysts

1
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investi — primary completion2023-11-09

Facts & assertions

4 sourced
Enrollment
463
Phase
PHASE3
Primary Completion Date
2023-11-09
Status
TERMINATED
relationships
The graph out of here
drug
Ulotaront
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication